CORAL SPRINGS, Fla. — Global pharmaceutical company Lupin announced plans to build a new, state-of-the-art manufacturing facility in Coral Springs, Florida, representing a projected $250 million investment over five years. The expansion underscores Lupin’s commitment to strengthening U.S.-based pharmaceutical production, particularly in critical respiratory therapies.
The new 70,000-square-foot site, located on more than five acres, will have the capacity to produce more than 25 essential respiratory medicines, including lifesaving albuterol inhalers for children and service members. The facility is expected to generate over 200 skilled jobs by 2030 and bolster domestic manufacturing resilience and supply chain security.
“The expansion of Lupin’s footprint in Coral Springs is a core part of our growth strategy,” said Christoph Funke, Chief Technical Operations Officer, Lupin. “This new state-of-the-art facility will build on our existing presence in Florida, which is home to Lupin’s headquarters and our Advanced Inhalation Research Center. This investment demonstrates Lupin’s commitment to innovation, quality and supply chain reliability — and our ability to partner with Florida’s leaders to strengthen America’s medicine security by growing our capacity to produce affordable treatments for patients. We are grateful to Florida’s leadership for their partnership in making this possible.”
Florida Secretary of Commerce J. Alex Kelly hailed the announcement as a major win for the state’s life sciences sector.
“Thanks to Governor DeSantis’ leadership, Florida has built a strong foundation for growth—with a strong focus on research and development, nine consecutive years as the #1 state for postsecondary education and three consecutive years as the #1 state for talent development,” Kelly said. “Lupin’s investment will strengthen Florida’s position as a leader in life sciences, boost our advanced manufacturing capabilities and enhance the state’s medicine security—delivering long-term benefits to both our economy and the health of Floridians.”
The Coral Springs facility will anchor U.S. production of respiratory therapies while diversifying the supply chain to ensure affordable, reliable access to essential medicines—from routine pediatric care to pandemic-scale demand. Lupin will also receive state tax credits and incentives for its investment and job creation commitments, working in partnership with FloridaCommerce/Select Florida, the City of Coral Springs, the Greater Fort Lauderdale Alliance, and the Broward County Commission.
CDR
